Unsafe
Mostly Not Aligned
Patient Risk:
Low
Summary
Most extracted claims are not supported by the provided FDA label text. Only limited partial support exists for extended-release/once-daily dosing and the existence of an extended-release formulation; the majority of claims about brand/packaging naming and confusion/mix-ups are absent from the supplied label sections and cannot be validated.
Category Scores
Accurate Statements
Different names may reflect the formulation, including extended-release or long-acting tramadol.
Supported only in a limited sense by the presence of an extended-release/long-acting product description and extended-release capsule dosing (Sections 2.1 and 3). The label evidence provided does not address naming conventions or confusion risk.
Formulation labels matter because dosing schedules can differ.
Partially supported: the label states Tramadol Hydrochloride Extended-Release Capsules are administered orally once daily (Section 2.1), which is consistent with different dosing schedules by formulation.
Unsupported Statements
Tramadol is marketed under many different brand and generic names worldwide.
Not supported by the provided label sections.
Common ways tramadol is written include: Tramadol (generic).
Not supported by the provided label sections.
Common ways tramadol is written include: Tramadol hydrochloride.
Not supported by the provided label sections.
Tramadol hydrochloride is often shown on packaging and labels.
Not supported by the provided label sections.
Tramadol is commonly sold in the US under brand and generic product names that include 'tramadol' as the active ingredient.
Not supported by the provided label sections.
Exact brand availability changes over time.
Not supported by the provided label sections.
Different names may reflect the formulation, including immediate-release tramadol.
Not supported by the provided label sections.
Extended-release or long-acting tramadol products may be labeled as 'ER' or 'extended release'.
Not supported by the provided label sections.
Tramadol product names and formulations can be mixed up.
Not supported by the provided label sections.
Immediate-release versus extended-release dosing can be mixed up.
Not supported by the provided label sections.
Combination products (if present in your country) versus tramadol alone can be mixed up.
Not supported by the provided label sections.
Contradictions
Important Omissions
No label-supported statement was provided clarifying the specific FDA-supported administration safeguards for extended-release misuse (e.g., swallowing whole; not breaking/chewing/splitting/dissolving; dose limits; not concomitantly with other tramadol products).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The challenged claims primarily concern market naming/packaging and potential confusion rather than explicit FDA dosing restrictions. However, because the claims are largely not label-supported and do not reflect the specific label safety instructions for extended-release administration, there is a risk of misalignment with FDA-prescribing guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Not Aligned
Primary Issue
Most claims are absent from the provided FDA label sections and cannot be substantiated. Only limited partial support exists for the extended-release formulation and once-daily administration.
Suggested Improvement
Restrict statements to label-supported content in the provided sections (e.g., that the product is extended-release, once-daily, administered orally, and that extended-release capsules should be swallowed whole; do not co-use with other tramadol products; do not exceed 300 mg/day). Avoid broad assertions about brand naming practices and formulation mix-up without label support.